European Journal of Pharmaceutical Sciences 2000-02-01

Complexation of the interferon inducer, bropirimine, with hydroxypropyl-beta-cyclodextrin.

M Echezarreta-López, J J Torres-Labandeira, L Castiñeiras-Seijo, L Santana-Penín, J L Vila-Jato

Index: Eur. J. Pharm. Sci. 9(4) , 381-6, (2000)

Full Text: HTML

Abstract

Bropirimine (ABPP) is an orally active immunomodulator that increases endogenous alpha-interferon and other cytokines used clinically against carcinoma in situ of the bladder. The oral absorption of ABPP is poor because its low solubility in water. The purpose of this study is to develop a technological procedure useful to increase the water solubility of ABPP. To this end, the interaction of ABPP with several cyclodextrin derivatives-alpha-, beta-, gamma- and hydroxypropyl-beta-cyclodextrin with a degree of substitution 2.7 (HPbetaCD) was studied and the effect of the complexation process on the water solubility of the drug was evaluated. The best results were obtained with the hydroxypropyl derivative, HPbetaCD, that interacts in a 1:1 drug:cyclodextrin molar ratio. The inclusion complex ABPP-HPbetaCD was characterized in solution by nuclear magnetic resonance (1H-NMR). The solid inclusion complex was obtained by freeze-drying and characterized by differential scanning calorimetry (DSC), X-ray diffractometry and mass spectrometry. The dissolution rate of ABPP from the HPbetaCD solid inclusion complex was increased compared to the powdered drug but not differences were found between the complex and a physical mixture with a similar molar ratio. The increase of the dissolution rate of the drug can be attributed to the breakdown in solution of the drug dimers in the presence of the cyclodextrin and to the complex formation.


Related Compounds

Related Articles:

CMV specific cytokine release assay in whole blood is optimized by combining synthetic CMV peptides and toll like receptor agonists.

2014-12-01

[J. Immunol. Methods 414 , 82-90, (2014)]

Bropirimine, an orally active anticancer agent for superficial bladder cancer.

1998-08-01

[Eur. Urol. 34(2) , 107-10, (1998)]

Current and new strategies in immunotherapy for superficial bladder cancer.

2004-09-01

[Urology 64(3) , 409-21, (2004)]

Paclitaxel, bropirimine and linomide: effect on growth inhibition in a murine prostate cancer model by different growth regulatory mechanisms.

1998-03-01

[Methods Find. Exp. Clin. Pharmacol. 20(2) , 111-4, (1998)]

Bropirimine as neoadjuvant therapy decreases residual disease and expression of markers PCNA and TGF-beta 1 in a rat orthotopic prostate adenocarcinoma.

1997-05-01

[Methods Find. Exp. Clin. Pharmacol. 19(4) , 261-7, (1997)]

More Articles...